^
Association details:
| Biomarker: | BRCA2 mutation |
|---|---|
| Cancer: | Cholangiocarcinoma |
| Drug: | Lynparza (olaparib) (PARP inhibitor) |
| Direction: | Sensitive |
Evidence:
Title:
Lynparza approved in Japan for the treatment of advanced ovarian, prostate and pancreatic cancers
Excerpt:
AstraZeneca and MSD’s Lynparza (olaparib) has been approved in Japan for the treatment of advanced ovarian, prostate and pancreatic cancers….The three approvals authorise Lynparza for:...maintenance treatment after platinum-based chemotherapy for patients with BRCAm curatively unresectable pancreas cancer.
Source:
Title:
Olaparib in Treating Patients With Metastatic Biliary Tract Cancer With Aberrant DNA Repair Gene Mutations
Excerpt:
...somatic mutations in ATM, ATR, CHEK2, BRCA 1/2, RAD51, BRIP1, PALB2, PTEN, FANC, NBN, EMSY, MRE11, ARID1A] or germline mutations in the above genes....
Trial ID:
Source:
Title:
Alterations in DNA Damage Repair Genes in Primary Liver Cancer
Excerpt:
Herein, we explored eight BRCAness patients with seven ICC and 1 H-ChC, who were all treated with olaparib (a PARPi)...three patients who achieved partial response had germline BRCA2 mutations and family cancer history, highlighting that patients with ICC with BRCA2 germline mutations may be more sensitive to PARPi therapy.
DOI:
10.1158/1078-0432.CCR-19-0127
Trial ID:
Source:
Title:
Comprehensive molecular profiling of intrahepatic cholangiocarcinoma in the Chinese population and therapeutic experience
Excerpt:
Samples from 122 individual patients with ICC were analyzed….BRCA1/2 mutations were detected in 16 (13%) patients...Four patients accepted poly ADP-ribose polymerase (PARP) inhibitor (olaparib) treatment combined with chemotherapy. Two patients achieved stable disease, and two patients responded partially.
Secondary therapy:
Chemotherapy
DOI:
https://dx.doi.org/10.1186%2Fs12967-020-02437-2
